What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call

Key Points

• RASONQUE generated $197.6 million in U.S. net product revenue during roughly five weeks on the market, with more than 5,000 patients treated. Executives cautioned that early sales included finite groups transitioning from expanded access or waiting for approval, so it is too soon to assess the launch’s normalized trajectory.
• Revolution Medicines advanced several late-stage trials, including completing U.S. enrollment in the first-line pancreatic cancer RASolute 303 study and beginning dosing in RASolute 309. The company expects a 2027 initial readout from its phase III lung cancer study and is launching a phase III colorectal cancer trial.
• The company’s quarterly net loss widened to $407.5 million as R&D and commercial expenses increased; it ended the quarter with $3.7 billion in cash and marketable securities. Management reiterated 2026 operating expense guidance of $2.1 billion to $2.2 billion and expects spending to rise in 2027.

Revolution Medicines NASDAQ: RVMD reported $197.6 million in third-quarter net product revenue from its newly approved pancreatic cancer treatment RASONQUE, reflecting roughly five weeks of U.S. sales and treatment of more than 5,000 commercial patients.

Executives cautioned that the initial sales figure included patients transitioning from an expanded access program and others who had exhausted available treatments while awaiting the drug’s approval. Both groups represent finite sources of early demand, Chief Global Commercialization Officer Anthony Mancini said on the company’s earnings call.

The company reported a net loss of $407.5 million for the quarter ended Sept. 30, 2026, compared with $305.2 million a year earlier, as research, development and commercial spending rose.

Early launch includes patients awaiting treatment

The Food and Drug Administration approved RASONQUE on Aug. 26 for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multi-agent systemic therapy. The company began making the oral medicine available by prescription immediately after approval, Chairman and CEO Mark Goldsmith said.

Mancini said early demand reflected three groups: patients moving from the expanded access program to commercial supply, patients who had exhausted other treatment options, and newly eligible patients starting treatment after approval. The U.S. transition for expanded access patients continuing treatment was complete by the end of October, he said.

A meaningful portion of the initial patients were later in their disease course and had lower performance status, potentially leading to shorter treatment durations, Mancini said. He declined to provide a detailed breakdown of the groups or additional October demand figures.

“With only five weeks of commercialization activity, it is too early to draw conclusions about the normalized trajectory of the launch,” Mancini said.

Approximately 2,700 unique health care providers prescribed RASONQUE during the quarter. Utilization was about 40% in academic settings and 60% in community settings, Mancini said. He added that most patients seen so far had previously treated metastatic pancreatic cancer.

RASONQUE claims had been reimbursed across health plans collectively representing more than 90% of covered U.S. pancreatic ductal adenocarcinoma patients, according to Mancini. Most formal coverage policies were still being developed, and he cautioned that some claims reimbursed during this early period might not be reimbursed once those policies are established.

Guidelines and international plans

Goldsmith said National Comprehensive Cancer Network guidelines include RASONQUE as a category 1 preferred subsequent therapy option for appropriate patients with locally advanced or metastatic pancreatic cancer, as well as recurrent disease following prior systemic therapy. The guidelines also list the drug as useful in certain first-line metastatic circumstances.

The recommendations extend beyond the FDA-approved metastatic indication but do not change it, Goldsmith said. The guidelines also include RASONQUE as a category 2A available targeted agent for metastatic non-small cell lung cancer with certain KRAS mutations, although the drug remains investigational in lung cancer.

In Europe, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion in October for daraxonrasib, the medicine marketed in the U.S. as RASONQUE, as monotherapy for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. A European Commission decision remains pending.

Mancini said the company is preparing for European reimbursement and country-level launches, with timing dependent on approval and local access requirements. It is also preparing for a potential launch in Japan.

Pipeline trials advance

Chief Development Officer Alan Sandler said U.S. enrollment was complete in RASolute 303, a phase III study of RASONQUE alone and with chemotherapy in first-line metastatic pancreatic cancer. Global enrollment is expected to finish in the first half of 2027.

The company has begun dosing patients in RASolute 309, a phase III trial combining RASONQUE and zoldonrasib in first-line RAS G12D pancreatic cancer. Other phase III pancreatic studies include RASolute 304 in the adjuvant setting and RASolute 305, which evaluates zoldonrasib with chemotherapy in the first-line setting.

The FDA granted breakthrough therapy designation to the investigational combination of RASONQUE, gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer, Goldsmith said. The agency also granted orphan drug designation to zoldonrasib for pancreatic cancer.

In previously treated RAS-mutant non-small cell lung cancer, Revolution Medicines expects all sites in its phase III RASolve 301 study to close enrollment by the end of November, with an initial readout planned for 2027, Sandler said.

The company is also initiating RASonate 312, a global phase III colorectal cancer trial testing zoldonrasib with cetuximab and chemotherapy against standard of care. BeOne Medicines is funding and conducting the study on Revolution Medicines’ behalf. Sandler said the company expects to provide an earlier-stage colorectal cancer data update and the trial design in the first half of 2027.

Spending rises alongside launch

Chief Financial Officer Jack Anders said third-quarter revenue included initial stocking, with less than two weeks of inventory in the distribution channel at quarter-end. Cost of sales was $0.3 million, but Anders said that figure was not representative of a normal quarter because some products sold had been manufactured before approval and previously expensed as research and development.

Research and development expenses rose to $417.1 million from $262.5 million a year earlier, while selling, general and administrative expenses increased to $153.3 million from $52.8 million. The net loss included a $40.7 million noncash charge related to a change in the fair value of warrants assumed in the EQRx acquisition.

Revolution Medicines ended the quarter with $3.7 billion in cash equivalents and marketable securities, excluding $250 million in debt proceeds received in October under its Royalty Pharma funding arrangement. Anders reiterated 2026 operating expense guidance of $2.1 billion to $2.2 billion and said the company expects 2027 operating expenses to rise from its current run rate.

About Revolution Medicines (NASDAQ:RVMD)

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company's research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.